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Bone morphogenetic protein-2 enhances bone formation when
delivered by a synthetic matrix containing
hydroxyapatite/tricalciumphosphate
Abstract
PURPOSE: The aim of the present study was to test whether or not a synthetic matrix consisting of a
polyethylene glycol (PEG) hydrogel containing recombinant human bone morphogenetic protein-2
(rhBMP-2) combined with grafting materials enhances bone regeneration compared with grafting alone
or empty control sites. MATERIAL AND METHODS: In each of 10 rabbits, four titanium cylinders
were screwed in perforated slits made in the external cortical bones of the calvaria. The following four
treatment modalities were randomly allocated: (1) empty control, (2) a combination of a PEG matrix and
hydroxyapatite/tricalciumphosphate (HA/TCP) granules and a combination of a PEG matrix containing
either 10 microg/ml (3) or 30 microg/ml (4) of BMP-2 and HA/TCP granules. After 8 weeks, the
animals were sacrificed and ground sections were obtained for histological analysis. For statistical
analysis repeated measures ANOVA and subsequent pairwise Student's t-test were applied (P<0.01).
RESULTS: Histomorphometric analysis showed an average area fraction of newly formed bone of
13.96+/-5.98% for the empty control, 15.16+/-7.95% for the PEG and HA/TCP group, 26.32+/-8.56%
for the group containing 10 mug rhBMP-2/ml, and 30.15+/-7.63% for the group containing 30 microg
rhBMP-2/ml. Statistical analysis revealed significantly more newly formed bone in the two rhBMP-2
groups compared with the PEG and HA/TCP group and with the empty control. Regarding the surface
fraction of the HA/TCP graft particles covered with newly formed bone the addition of rhBMP-2
revealed a more than two-fold increase compared with cylinders containing HA/TCP granules without
rhBMP-2. This difference reached statistical significance. CONCLUSIONS: It is concluded that
rhBMP-2 significantly enhances bone regeneration in rabbits when delivered by a synthetic matrix
containing HA/TCP. This synthetic PEG matrix containing HA/TCP granules apparently fulfills a
number of criteria required for an ideal carrier system for rhBMP-2.
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Purpose: The aim of the present study was to test whether or not a synthetic matrix consisting of a 
polyethylene glycol (PEG) hydrogel containing rhBMP-2 combined with grafting materials enhances 
bone regeneration compared to grafting alone or empty control sites.  
Materials and Methods: In each of 10 rabbits, 4 titanium cylinders were screwed in perforated slits 
made in the external cortical bones of the calvaria. The following 4 treatment modalities were randomly 
allocated: (1) empty control, (2) a combination of PEG matrix and hydroxyapatite/tricalciumphosphate 
(HA/TCP) granules and a combination of PEG matrix containing either 10µg/ml (3) or 30µg/ml (4) of 
BMP-2 and HA/TCP granules. After 8 weeks, the animals were sacrificed and ground sections were 
obtained for histological analysis. For statistical analysis repeated measures ANOVA and subsequent 
pairwise Student's t-test were applied (p<0.01). 
Results: Histomorphometric analysis showed an average area fraction of newly formed bone of 
13.96±5.98% for the empty control, 15.16±7.95% for the PEG and HA/TCP group, 26.32±8.56% for 
the group containing 10µg rhBMP-2/ml, and 30.15±7.63% for the group containing 30µg rhBMP-2/ml. 
Statistical analysis revealed significantly more newly formed bone in the two rhBMP-2 groups 
compared to the PEG and HA/TCP group and to the empty control. Regarding the surface fraction of 
the HA/TCP graft particles covered with newly formed bone the addition of rhBMP-2 revealed a more 
than two fold increase compared to cylinders containing HA/TCP granules without rhBMP-2. This 
difference reached statistical significance. 
Conclusion: It is concluded that rhBMP-2 significantly enhances bone regeneration in rabbits when 
delivered by a synthetic matrix containing HA/TCP. This synthetic polyethylene-glycol matrix 




Bone morphogenetic proteins, a subfamily of the transforming growth factor-ß superfamily, were 
discovered based on the bone-inductive activity sheltered in bone matrix (Urist 1965). One of these 
proteins, recombinant human bone morphogenetic protein-2 (rhBMP-2) has been shown to induce bone 
formation in a variety of indications.  A large number of animal and human studies have documented the 
successful use of rhBMP-2 to induce and enhance bone regeneration for mandibular resection defects 
(Toriumi et al. 1991; Boyne 1999), for cleft palate defects (Boyne et al. 1998), for alveolar ridge defects 
(Cochran et al. 1999; Barboza et al. 2000; Jung et al. 2003), and for sinus floor augmentations (Nevins et 
al. 1996; Boyne et al. 1997). In addition, it has been shown that dental implants placed in bone induced 
by rhBMP-2 osseointegrate and respond to long-term functional loading much like dental implants 
placed in native alveolar bone (Jovanovic et al. 2003). 
Various biomaterials have been tested as carriers for rhBMP-2 in craniofacial preclinical models 
(Wikesjö et al. 2003). These include an absorbable collagen sponge (ACS) (Boyne et al. 1997; Howell et 
al. 1997), decalcified bone matrix (Toriumi et al. 1991; Sigurdsson et al. 1996), hyaluronan (Hunt et al. 
2001), deproteinized bovine bone matrix (Jung et al. 2003), hydroxyapatite (Koempel et al. 1998), 
calcium phosphates (Wikesjö et al. 2002), polylactic acids (Weber et al. 2002) and polymethylethyl-
methacrylate (Boyne & Shabahang 2001).  
In spite of the large amount of preclinical and clinical studies with various biomaterials, rhBMP-2 has 
not yet found the way into clinical practice in dentistry. Economic reasons and problems encountered 
with the lack of an ideal carrier system might be responsible for this. ACS is the most frequently used 
carrier system for rhBMP-2 and has been extensively tested (Howell et al. 1997; Cochran et al. 1999). 
Collagen can bind BMPs to some degree and is readily infiltrated by cells and remodeled into bone 
tissue (Lutolf et al. 2003). However, like other natural polymers, it has some limitations in clinical use, 
primarily because of the lack of space maintenance, the difficulty to engineer its properties, and its 
immunogenicity (Sigurdsson et al. 1996; Barboza et al. 2000). In order to improve the space 
maintenance of ACS the use of barrier membranes for guided bone regeneration have successfully been 
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applied (Wikesjö et al. 2003). In contrast, recent experimental studies reported that bone formation 
following application of rhBMP-2 in conjunction with barrier membranes was delayed and results were 
hampered, when the membrane was exposed and subsequent infections occurred (Cochran et al. 1999; 
Jovanovic et al. 2003).  
A synthetic carrier material which enables vascular and cellular ingrowth and which is space-providing 
would, therefore, be desirable to define the spatial configuration of the induced bone. In recent animal 
studies it was demonstrated that hydrogels made of polyethylene glycol (PEG) fulfill a number of 
criteria required to serve as in situ forming matrix for optimal cell ingrowth and retention of bioactive 
proteins (Lutolf et al. 2003; Jung et al. [a]). In one study it was shown that the release kinetics of 
rhBMP-2 could be controlled by entrapping the rhBMP-2 into the synthetic PEG matrix (Lutolf et al. 
2003). The results showed efficient and highly localized bone formation. Although this material is a 
promising candidate for a successful carrier material the gel might not have sufficient mechanical 
stability to provide space for bone regeneration in larger defects. Therefore, it was suggested to combine 
the PEG material with a grafting material exhibiting osteoconductive properties (Hartman et al. 2005; 
Jung et al. [b]). 
The aim of the present study was to test whether or not a synthetic matrix made of polyethylene glycol 
(PEG) containing rhBMP-2 combined with hydroxyapatite /tricalciumphosphate granules enhances bone 
regeneration. The hypothesis was that the rhBMP-2 leads to more bone formation than the grafting 






Materials and Methods 
Animals 
The present animal investigation was evaluated and approved by the responsible Animal Research 
Ethics Committee at the University of Zurich, Switzerland. 10 adult (12 months old) New Zealand 
White rabbits, weighing between 3 and 4 kg, were used in the present study. The animals were kept in a 
purpose-designed room for experimental animals and were fed a standard laboratory diet. 
 
 
Synthetic matrix and bone morphogenetic proteins 
The present study employed a polyethylene glycol-based hydrogel as a synthetic matrix and carrier 
system for rhBMP-2. Preparation of the gel was performed similar to previously published protocols 
(Elbert et al. 2001; Jung et al. [a]). In brief, the elastic gel network was formed by reacting of 
stoichiometric amounts of a 4-arm PEG with acrylate endgroups and a linear PEG with thiol endgroups 
(Nektar Therapeutics, Huntsville AL) in an aqueous buffer system (2 mM HCl ). 
For the control gels a 9 amino acid cys-RGD peptide (Bachem, Bubendorf, Switzerland) was added to 
the PEG-acrylate solution. The BMP containing test gels were identical to the control gels with the 
exception that 10 or 30 µg of rhBMP-2 in a 2 mM HCl solution were mixed into the PEG solution (2 
mM HCl). The final concentrations amounted to 350 μg/g gel for the cys-RGD and to 10 or 30 μg/ml gel 
for the rhBMP-2, respectively. 
 
Surgical procedure 
Anesthesia of the 10 animals was initiated by injection of 65 mg/kg of ketamine and 4 mg/kg of xylazine 
and maintained with isofluoran/O2. The surgical procedure and the augmentation device have been 
comprehensively described in a previous paper (Jung et al. [b]). At the cranium of each rabbit a full 
thickness flap was elevated to expose the right and the left parietal and frontal bones. Four evenly 
distributed 6 mm diameter circular slits with 1 mm sink depth and perforations of the external cortical 
plate inside the slits were prepared. Subsequently, a specially designed cylinder made of c.p. titanium 
with a machined surface was screwed in each of the slits obtaining primary stability. The cylinders 
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measured 7 mm in height and 7 mm in outer diameter and exhibited a screw design towards the bone site 
and a small shoulder for a titanium lid towards the covering skin flap (Fig.1). 
One of the cylinders served as a first control and was left empty. Another cylinder served as a second 
control and was augmented with a combination of the RGD modified PEG matrix and 0.15 g of 
hydroxyapatite (HA) / tricalciumphosphate (TCP) granules (Straumann Bone Ceramic®; Institut 
Straumann AG, Basel, Switzerland). The granules were highly porous and had a size range of 500–1000 
μm. The 2 remaining cylinders served as test sites and were augmented with a combination of the RGD 
modified PEG matrix containing either 10 µg/ml (test 1) or 30 µg/ml (test 2) of rhBMP-2 and the 
HA/TCP granules. The cylinders were assigned in a random systematic manner. For the first animal the 
treatment modalities were randomly chosen for the four sites. In all subsequent animals the sequence of 
the treatment modalities was kept but the locations were stepwise rotated by one position in clockwise 
direction. For the cylinders containing PEG and the granules the PEG matrix in its liquid form was 
mixed with the HA/TCP granules for about 10 seconds. Subsequently, this putty-like mixture was 
placed into the determined cylinders. Within 60 seconds, the PEG gels set and thus stabilized the 
HA/TCP granules. The cylinders were left open towards the bone but were closed with a titanium lid 
towards the covering skin-periosteal flap (Fig.2). The periosteum and the cutaneous flap were adapted 
and sutured for primary healing.  
Eight weeks later, the rabbits were sedated with barbiturates and sacrificed by an overdose of Ketamin. 
The skull containing all 4 cylinders was removed and placed in 40% ethanol.  
 
Histologic preparation  
The samples were dehydrated in a graded series of increasing ethanol concentrations. Thereafter, they 
were embedded in methylmethacrylate without being decalcified according to standard procedures 
(Schenk et al. 1984). The specimens were sectioned in the frontal plane through the middle of the 
cylinders. Sections of 200µm thickness were obtained, ground and polished to a uniform thickness of 




Quantitative evaluation of bone regeneration was assessed by applying standard morphometrical tech-
niques (Weibel 1980; Gundersen et. al. 1988). Measurements were carried out directly in the light mi-
croscope at a magnification of 160x, using an optically superimposed eyepiece test grid composed of 
100 points and 10 cycloid lines (Schenk & Olah 1980). The number of test points overlying the profiles 
of the different components (i.e. mineralized bone tissue, non-mineralized tissue and graft particles) 
were counted. They are defined and symbolized according to the standard nomenclature of the Interna-
tional Society for Stereology (Exner 1987). The graft to bone contact was calculated by the number of 




Mean values and standard deviation were calculated for the area fraction of new bone formation within 
the cylinders and for the graft to bone contact. Values were displayed as box-plots ranging from the 25th 
(lower quartile) to the 75th (upper quartile) percentile including the mean and whiskers showing the 
minimum and maximum values. For statistical analysis repeated measures ANOVA and subsequent 
pairwise Student's t-test with corrected p-values according to Bonferroni were used to detect the 
differences between the 4 treatment modalities. 
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Results 
During the experiment, all animals showed uneventful healing of the area of surgery. No reductions in 
body weights were noted, and no postoperative infections were observed. Upon specimen retrieval one 
cylinder from the control group with HA/TCP without rhBMP-2 was found to be dislocated from the 
skull bone because of loss of fixation and was embedded in soft connected tissue. This cylinder was, 
therefore, excluded from further analysis. The remaining 39 cylinders were found to be stable and in the 




The external and internal cortical plates of the cranium were clearly visible on the histological 
specimens. The threaded base of all cylinders was well integrated in the external cortical plate of the 
skull. In rare situations new bone formation was found on the outside of the cylinders apparently 
climbing from the external skull base upwards along the outside wall of the cylinder. 
The staining allowed a clear distinction between the graft material and the regenerated bone. New bone 
formation within the cylinder space seemed to occur from the skull. The area closer to the covering lid 
showed a lower bone density than the area closer to the skull. Apparently, perforations through the 
external cortical plate served as the pathways through which new bone formation invaded the cylinder 
space. 
Tissue fill inside the cylinders varied strongly between the experimental groups. The empty control 
group demonstrated more or less tissue formation occupying about half the cylinder volume (Fig. 3). 
The groups containing HA/TCP granules revealed an even distribution of the granules within the entire 
cylinder, indicating that the PEG gels stabilized the granules within the cylinder. A large variability of 
granule sizes was observed within a given cylinder as well as between cylinders. In the HA/TCP 
containing cylinders newly formed bone trabeculae frequently bridged the spaces between the granules 
(Fig. 4). Within the area delimited by the regenerated bone a high degree of bone to graft contact was 
discernible. This indicated osteoconductive properties of the HA/TCP. To the naked eye the mount of 




Quantitative histomorphometry revealed that both groups containing rhBMP-2 showed a significantly 
increased amount of newly formed bone within the cylinders compared to the control groups. Average 
area fractions of newly formed bone after 8 weeks amounted to 13.96±5.98% for the empty control 
group, to 15.16±7.95% for the HA/TCP group, to 26.32±8.56% for the group containing 10µg rhBMP-
2/ml, and to 30.15±7.63% for group containing 30µg rhBMP-2/ml. Statistical analysis revealed that the 
area fraction of newly formed bone in the empty controls was not statistically significantly different 
from the group containing HA/TCP granules without rhBMP-2. Similarly, the difference in area fraction 
of newly formed bone in the two BMP-containing groups did not reach statistical significance. However, 
highly statistical significant difference in area fraction of newly formed bone was observed for both two 
groups containing BMP (10µg/ml and 30µg/ml) compared to two groups without the growth factor 
(control and HA/TCP alone) (Table 1 and Fig. 7).  
The surface fraction of bone substitute particles covered with newly formed bone is shown in Table 2 
and Figure 8. The addition of rhBMP-2 to the HA/TCP granules revealed a more than two fold increase 
in bone to graft contact. Compared to the HA/TCP granules alone (22.95±17.35) the addition of 10µg/ml 
(47.51±18.74) and 30µg/ml rhBMP-2 (55.18±19.67) revealed a highly statistically significant 




The present study demonstrated that the combination of a polyethylene glycol (PEG) matrix containing 
rhBMP-2 together with HA/TCP granules significantly increased the amount of bone regeneration. This 
was documented by significantly more bone formation and by significantly more bone to graft contact 
compared to control sites treated without rhBMP-2.  
A large variety of carrier and matrix systems have been tested for the application of rhBMP-2 in animal 
models (Wikesjö et al. 2003). It has been suggested that a successful candidate carrier system should 
provide optimal conditions for vascular and cellular in growth, and for release kinetics of growth factors 
(Brekke & Toth 1998). The carrier system should further be reproducible, nonimmunogenic, moldable, 
and space providing (Wikesjö et al. 2003). In recent animal studies it has been shown that fibrin as a 
carrier system for growth factors fulfills a number of criteria for an ideal matrix (Bruder & Fox 1999; 
Schmoekel et al. 2004a; Jung et al. 2005). In addition to optimal cellular in growth properties, fibrin 
contains a variety of adhesion sites for cells. Furthermore, remodeling of the fibrin matrix takes place 
by cellular proteolytic activities during cell in growth. Nonetheless, the fibrin matrix is a product 
derived from human blood, and therefore, carries the potential risk for transmission of agents.  
In order to have a completely reproducible and nonimmunogenic carrier system mimicking some of the 
properties of fibrin, a synthetic matrix made of PEG has been investigated (Lutolf et al. 2003; Jung et 
al. [a]). A previous in vitro and in vivo study documented that PEG combines the advantages of 
synthetic materials and of native protein-based materials (Lutolf et al. 2003). It was shown that the use 
of PEG containing rhBMP-2 resulted in complete bone coverage of critical size cranial defects in rats 
similar to the use of a collagen matrix containing rhBMP-2. In contrast to this enzymatically degradable 
PEG material the present study used a hydrolytically degradable PEG matrix, which was first 
investigated in a recent animal study (Jung et al. [a]). It was demonstrated that this PEG matrix 
containing a covalently bound peptide of the parathyroid hormone (PTH1-34 ) beneficially affected bone 
regeneration to an amount similar to the use of autogenous bone.  
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In all of these studies using PEG as a matrix system for bioactive factors the matrix has been 
additionally optimized by incorporation of the peptide Arg-Gly-Asp (RGD peptide). The effect of RGD 
peptide on cell adhesion was first identified more than 20 years ago (Pierschbacher et al. 1984). In order 
to prove the cell adhesion properties of RGD incorporated into the PEG matrix a recent in vitro study 
was performed (Lutolf et al. 2003). It was shown that human fibroblasts migrated radially from cell 
clusters into the surrounding PEG matrix only if the matrix contained RGD. This improved cell 
attraction cause by the RGD peptide might also have an effect on bone formation. In a variety of 
experimental studies it was demonstrated that the addition of RGD to implant surfaces increases bone 
formation significantly compared to uncoated implants (Schaffner et al. 1999; Elmengaard et al. 2005; 
Schliephake et al. 2005). However, the present study revealed no significant increased bone formation 
in sites treated with PEG containing RGD without rhBMP-2 compared to the empty control sites. This 
might be explained by the fact that indeed undifferentiated cells grow into the cylinder but they might 
experience sufficient signals in order to become osteoblast cells. The possible synergistic effect of RGD 
and rhBMP-2 in the test cylinder need to be further investigated. 
An additional criterion for an ideal carrier material is that it is able to provide the space for 
regeneration. While it is recognized that collagen is one of the best researched carrier material, different 
studies have documented inadequate bone regeneration when collagen is used alone as a bone graft 
substitute (Barboza et al. 2000; Howell et al 1997). Increased regeneration volume has been shown 
when collagen was combined with grafting materials consisting of HA/TCP (Miranda et al. 2005; 
Arosarena et al. 2005). It has been concluded that HA/TCP combined with collagen appeared to be a 
suitable carrier for rhBMP-2. The presently used PEG gel without granules has been successfully used 
in self-containing bone defects (Jung et al. [a]). Because the hydrogel alone might have insufficient 
mechanical properties for larger bone augmentation procedures, the combination of the PEG matrix 
with HA/TCP granules was tested in the present study. It could be shown that the combination of the 
PEG matrix with HA/TCP and rhBMP-2 was effective in augmenting the entire test cylinders. This was 
documented be a two-fold increase of newly formed bone in the rhBMP-2 treated sites compared to the 
control sites.  Although, the higher rhBMP-2 concentration (30μg/ml) showed slightly higher amounts 
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of newly formed bone compared to the lower concentration (10μg/ml) a statistically significant 
difference could not be observed. This indicates that a 3-fold increase of the rhBMP-2 concentration 
within the PEG matrix did not significantly improve bone regeneration in this augmentation model. A 
recent study using a similar animal model with two titanium cylinders on the rabbit skull compared the 
effect of demineralized bovine bone mineral and autogenous bone on bone augmentation within the 
cylinders (Slotte et al. 2003). For augmentation with autogenous bone 17.3% and for demineralized 
bovine bone mineral 19.9% newly formed bone was found within the cylinders after 12 weeks of 
healing (Slotte et al. 2003). In the present study both rhBMP-2 concentrations revealed a higher amount 
of newly formed bone (26.3 and 30.2%, respectively) after 8 weeks. Hence, within a shorter time period 
more bone was regenerated by the use of rhBMP-2 applied in a PEG matrix containing HA/TCP 
compared to a study using either autogenous bone or demineralized bovine bone mineral. From a 
clinical point of view, it may be speculated that the investigated grafting material can be used for bone 
defects that are nowadays recommended to augment with autogenous bone grafts. This in combination 
with the shorter healing time would represent an important step forward in simplifying bone 
augmentation procedures. 
The osteoconductive properties of the HA/TCP granules in combination with the PEG hydrogel could 
be observed in all groups. Considerable amounts of new bone had formed in direct contact with the 
HA/TCP granules. Furthermore, the rhBMP-2 treated sites showed a 2 to 2.5 fold increased bone to 
graft contact compared to sites treated with HA/TCP without rhBMP-2. This is in agreement with a 
randomized clinical trial showing a similar two-fold increase of bone to graft contact when a 
demineralized bovine bone mineral was combined with rhBMP-2 (Jung et al. 2003). Comparable 
amounts of graft to bone contacts could be detected between the control cylinders with HA/TCP 
(22.95%) and a recent study using demineralized bovine bone minerals (24.93%) for augmenting 
cylinders in a similar animal model (Slotte et al. 2003). 
The present study used rhBMP-2 concentrations of 10 and 30μg/ml. This is at least 10 times less 
compared to the majority of experimental studies and about 50 to 100 times less compared to clinical 
studies using rhBMP-2 for bone regeneration (Boyne et al. 1997; Higuchi et al. 1999; Cochran et al. 
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1999; Miranda et al. 2005). It is known that the kinetics of protein release can greatly influence bone 
regeneration (Schmoekel et al. 2004b). Different studies reported a prolonged release of rhBMP-2 from 
hydrogels either made of PEG or gelatin (Hong et al. 1998; Lutolf et al. 2003). The presently used PEG 
hydrogel revealed an in vitro degradation of 13 days (Jung et al. [a]). Although the release kinetics of 
rhBMP-2 from the presently used PEG gel has not yet been evaluated, based on the above data a 
sustained release over 1 to 2 weeks might be anticipated. The slow and local release of rhBMP-2 might 
be critical in reducing the concentrations to a level, which is acceptable for clinical applications. 
It is concluded that rhBMP-2 significantly enhances bone regeneration in rabbits when delivered by a 
synthetic matrix containing HA/TCP. This synthetic polyethylene-glycol matrix containing HA/TCP 
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Table 1  Fraction of mineralized bone 
Condition Number of samples Mean (%) SD 
empty 9 13.96 5.98 
PEG 10 15.16 7.95 
PEG/BMP 10 10 26.32 8.56 
PEG/BMP 30 10 30.15 7.63 
 
 
Table 2  Bone to graft contact 
Condition Number of samples Mean (%) SD 
PEG 9 22.95 17.35 
PEG/BMP 10 10 47.51 18.74 















Fig.1:  Four titanium cylinders with a screw design towards the bone site were screwed in each of the 
slits obtaining primary stability. 
 
Fig. 2: After augmentation with the respective treatment modalities, the four cylinders will be closed 
with a titanium lid towards the covering skin-periosteal flap 
 
Fig. 3: Histological section of an empty control cylinder after 8 weeks of healing (Toluidine blue 
staining; new bone = light blue) 
 
Fig. 4: Histological section of a control cylinder augmented with a combination of PEG matrix and 
HA/TCP granules after 8 weeks of healing (Toluidine blue staining; new bone = light blue, 
HA/TCP granules = dark grey) 
 
Fig. 5: Histological section of a test cylinder augmented with a combination of PEG matrix containing 
10 µg/ml rhBMP-2 and HA/TCP granules after 8 weeks of healing (Toluidine blue staining; new 
bone = light blue, HA/TCP granules = dark grey) 
 
Fig. 6: Histological section of a test cylinder augmented with a combination of PEG matrix containing 
30 µg/ml rhBMP-2 and HA/TCP granules after 8 weeks of healing (Toluidine blue staining; new 
bone = light blue, HA/TCP granules = dark grey) 
 
Fig. 7 and 8: 
Values of area fraction of newly formed bone (Fig. 7) and bone to graft contact (Fig. 8) are 
displayed as box-plots ranging from the 25th to the 75th percentile including the mean and 
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